Two-way Regulation of Intestinal Microorganisms on Hyperuricemia and Gout

Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v6i4.4820

Shuo Cao¹, Jinfeng Wei¹, Hongbin Qiu¹, Qiushi Miao², Suo Wang¹, Ran Xue¹

1. School of Public Health of Jiamusi University, Jiamusi 154007, Heilongjiang, China
2. Department of Gastroenterology, First Affiliated Hospital of Jiamusi University, Jiamusi 154007, Heilongjiang, China

Abstract

In recent years, the two-way regulation of intestinal microorganisms in the pathogenesis of hyperuricemia and gout has attracted increasing attention. Studies have shown that specific probiotics can participate in the regulation of uric acid metabolism in many ways, including promoting intestinal uric acid excretion, inhibiting xanthine oxidase activity, enhancing intestinal barrier function and regulating immune infl ammatory response, thus effectively reducing blood uric acid level and alleviating the onset of gouty arthritis. On the contrary, colonization or flora imbalance of conditional pathogenic bacteria can induce chronic inflammation, destroy intestinal mucosal barrier, inhibit uric acid excretion, and further aggravate metabolic disorder. Metagenomics further revealed that some intestinal flora can degrade purine metabolites and regulate purine homeostasis. To sum up, intestinal microorganisms affect uric acid homeostasis through metabolism and immunity, forming an interactive network of "flora-metabolism-inflammation". In the future, we should develop individualized intervention strategies based on probiotics, prebiotics and synthetic biology techniques, and provide a new path for the accurate prevention and treatment of hyperuricemia and gout.

Keywords

intestinal microorganisms; hyperuricemia; gout; probiotics

Full Text

PDF - Viewed/Downloaded: 2 Times

References

[1] ZHANG W. Hyperuricemia: current state and prospects [J]. Exploratory Research and Hypothesis in Medicine, 2025, 10(1): 49-55.
[2] HE H, GUO P, HE J, et al. Prevalence of hyperuricemia and the population attributable fraction of modifiable risk factors: evidence from a general population cohort in C hina [J]. Frontiers in Public Health, 2022, 10: 936717.
[3] DU L, ZONG Y, LI H, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy [J]. Signal Transduction and Targeted Therapy, 2024, 9: 212 ..
[4] MIYAZAKI R, OHASHI Y, SAKURAI T, et al. First verification of human small intestinal uric acid secretion and effect of ABCG2 polymorphisms [J]. Journal of Translational Medicine, 2025, 23: 257.
[5] KASAHARA K, KERBY R L, ZHANG Q, et al. Gut bacterial metabolism contributes to host global purine homeostasis[J]. Cell Host & Microbe, 2023, 31: 1038-1053.
[6] ZHAO S, FENG P Y, HU X G, et al. Probiotic Limosilactobacillus fermentumGR-3 ameliorates human hyperuricemia via degrading and promoting excretion of uric acid[J]. iScience, 2022, 25: 105198.
[7] YANG X, TANG J, ZENG X, et al. Probiotics in alleviating hyperuricemia: research status, mechanism of action and challenges[J]. Science and Technology of Food Industry, 2024, 45: 415-425.
[8] Lu Han, Zhao Kexin, Xue Yuling, et al. Research progress on the correlation between different dietary patterns mediated by intestinal flora and hyperuricemia [J]. Food Science, 2024, 45: 330-338.
[9] CAI X, ZHANG S, LAN T, et al. The relationship between dietary index for gut microbiota and hyperuricemia: a cross-sectional study using NHANES data[J]. Frontiers in Nutrition, 2025, 12: 1580122.
[10] ZHANG H, DA W, DONG L, et al. Lactobacillus paracaseiN1115 alleviates hyperuricemia in mice: regulation of uric acid metabolism as well as its impact on gut microbiota and s hort-chain fatty acids[J]. Frontiers in Nutrition, 2025, 12: 1651214.
[11] ZHANG W, WANG T, GUO R, et al. Variation of serum uric acid is associated with gut microbiota in patients with diabetes mellitus[J]. Frontiers in Cellular and Infection Microbiology, 2022, 11: 761757.
[12] MIYAZAKI R, OHASHI Y, SAKURAI T, et al. First verification of human small intestinal uric acid secretion and effect of ABCG2 polymorphisms[J]. Journal of Translational Medicine, 2025, 23(1): 257.
[13] MA J, PIAO X, MAHFUZ S, et al. The interaction among gut microbes, the intestinal barrier and short chain fatty acids[J]. Animal Nutrition, 2022, 9: 159-174.
[14] CUI Y, AN P, LI F, et al. Strategies to reduce uric acid through gut microbiota intervention[J]. Frontiers in Microbiology, 2025, 16: 1654152.
[15] YANG Y, WANG Y, HUANG J, et al. Influence of gut microbiota-derived butyrate on intestinal uric acid excretion and hyperuricemia regulation by Cichorium intybusL.[J] . International Journal of Molecular Sciences, 2025, 26(15): 6413.
[16] TSENG W T, KONG X R, HAN Y T, et al. Lacticaseibacillus paracaseiLT12—a probiotic strain that reduces hyperuricemia via inhibiting XO activity and regulating renal uric acid transp ortation protein[J]. Fermentation, 2025, 11(3): 96.
[17] HUSSAIN A, RUI B, ULLAH H, et al. Limosilactobacillus reuteriHCS02-001 attenuates hyperuricemia through gut microbiota-dependent regulation of uric acid biosynthesis and excretion[J]. Microorganisms, 2024, 12(3): 637.
[18] LV Q, ZHOU J, WANG C, et al. A dynamics association study of gut barrier and microbiota in hyperuricemia[J]. Frontiers in Microbiology, 2023, 14: 1287468.
[19] SINGH A K, DURAIRAJAN S S K, IYASWAMY A, et al. Elucidating the role of gut microbiota dysbiosis in hyperuricemia and gout: insights and therapeutic strategies[J]. World Journal of Gastroenterology, 2024, 30(40): 4404-4423.
[20] HU C. Regulating uric acid[J]. eLife, 2024, 13: e104493.
[21] GIORDANO L, AHMED S, VAN DER MADE T, et al. Gut microbial-derived short chain fatty acids enhance kidney proximal tubule cell secretory function[J]. Biomedicine & Pharmacotherapy, 2025, 188: 118214.
[22] MIYAJIMA Y, KARASHIMA S, MIZOGUCHI R, et al. Prediction and causal inference of hyperuricemia using gut microbiota[J]. Scientific Reports, 2024, 14(1): 9901.
[23] OTHMAN R B, SASSI M B, HAMMAMIA S B, et al. Effect of probiotics on uric acid levels: meta-analysis with subgroup analysis and meta-regression[J]. Nutrients, 2025, 17(15): 2467.
[24] RODRÍGUEZ J M, GARRANZO M, SEGURA J, et al. A randomized pilot trial assessing the reduction of gout episodes in hyperuricemic patients by oral administration of Ligilactobacillus salivar iusCECT 30632, a strain with the ability to degrade purines[J]. Frontiers in Microbiology, 2023, 14: 1111652.
[25] LIU X, KE L, LEI K, et al. Antibiotic-induced gut microbiota dysbiosis has a functional impact on purine metabolism[J]. BMC Microbiology, 2023, 23(1): 187.

Citing this article:

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License